House dust mite allergy drug, Odactra receives FDA approval
by Press Release from Outbreak News Today on (#2EE8Z)
The U.S. Food and Drug Administration today approved Odactra, the first allergen extract to be administered under the tongue (sublingually) to treat house dust mite (HDM)-induced nasal inflammation (allergic rhinitis), with or without eye inflammation (conjunctivitis), in people 18 through 65 years of age. "House dust mite allergic disease can negatively impact a person's quality of ["]
The post House dust mite allergy drug, Odactra receives FDA approval appeared first on Outbreak News Today.